Thippawan ChuenchitraVictoria R. PolonisChantapong WasiSuda LouisirirojchanakulSorachai NitayaphanRuengpung SutthentJosephine H. CoxMark S. De SouzaArthur E. BrownDeborah L. BirxArmed Forces Research Institute of Medical Sciences, ThailandMahidol UniversityHJFWalter Reed Army Institute of Research2018-07-242018-07-242003-04-01AIDS Research and Human Retroviruses. Vol.19, No.4 (2003), 293-305088922292-s2.0-0344490286https://repository.li.mahidol.ac.th/handle/20.500.14594/20910Identification of immune correlates associated with disease progression will provide information for HIV-1 vaccine design in countries such as Thailand, where the prevalent subtypes (B and CRF01_AE [E]) are characterized. In this study, plasma viral load and humoral immune responses were measured in 20 HIV-1 subtype E-infected Thai patients with different rates of disease progression, based on CD4+ T cell decline and clinical symptoms. Nine progressors (PRs) and 11 slower progressors (SPs) were evaluated. CD4+ T cell counts were inversely correlated with viral load (p = 0.004) and positively correlated with p24 Ab (p = 0.022). In progressors, p24 Ab showed a significant decrease (p < 0.001) over time. V3 and gp41 Ab did not change significantly in either group. Both CD4-binding site (CD4/gp120BS) and gp120 titers correlated positively with neutralizing antibody (NAb) against both a subtype E cell line-adapted virus (NP03) and a primary isolate (TH023). However, V3 Ab correlated only with NAb against NP03 (p < 0.001). Increased NAb over time was observed more frequently in SPs as compared with PRs, against both the TH023 (p = 0.004) and NPO3 (p= 0.004) viruses. Cross-clade antibody-dependent cellular cytotoxicity was demonstrated in both groups. These data suggest that in HIV-1 subtype E infection, declining p24 Ab titer is a predictive marker of disease progression, as described for subtype B. Furthermore, in subtype E-infected patients, slower progressors retain the immune competence to develop new antibody responses to Env over time; these evolving responses may contribute to prolonged survival during HIV-1 disease progression.Mahidol UniversityImmunology and MicrobiologyArticleSCOPUS10.1089/088922203764969492